Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

AIMS: To summarise evidence on tobacco addiction interventions published by the Cochrane Tobacco Addiction Group (CTAG) from 2019 to 2020. METHODS: Narrative summary of all new and updated Cochrane Reviews published by CTAG in 2019 and 2020, outlining key results and promising avenues for future research. RESULTS: CTAG published six new reviews and updated 15 reviews. There is high-certainty evidence that combining fast-acting nicotine replacement therapy (NRT) with transdermal patches helped more people to quit than single-form NRT (risk ratio (RR) 1.25, 95% confidence interval (CI) 1.15-1.36, 14 studies, n=11,356; I2 =4%), and moderate-certainty evidence that using NRT before quitting can increase quit rates more than using NRT from quit day onwards (RR 1.25, 95%CI 1.08-1.44, 9 studies, n=4395; I2 =0%;). Reducing smoking in order to quit completely results in similar quit rates to abrupt quitting (RR 1.01, 95%CI 0.87-1.17; I2 =29%; 22 studies, n=9219; moderate-certainty). Electronic cigarettes may help more people quit than NRT (RR 1.53, 95%CI 1.21-1.93; I2 =0%; 4 studies, n=1924; moderate certainty), nicotine-free electronic cigarettes (RR 1.94, 95%CI 1.21-3.13; I2 =0%; 5 studies, n=1447; moderate-certainty), and behavioural/no support (RR 2.61, 95%CI 1.44-4.74; I2 =0%; 6 studies, n=2886; very low-certainty). Varenicline may help prevent relapse in abstainers (RR 1.23, 95%CI 1.08-1.41; I2 =82%; 11 studies, n=1297; moderate-certainty), but behavioural support did not prevent relapse (RR 0.98, 95%CI 0.87-1.11; I2 =52%; 11 studies, n=5523; moderate-certainty). Financial incentives increased quit rates in the general population (RR 1.49, 95%CI 1.28-1.73; I2 =33%; 30 studies, adjusted n=20,097; high-certainty) and during pregnancy (RR 2.38, 95%CI 1.54-3.69; I2 =41%; 9 studies, n=2273; moderate-certainty). This overview also provides detail on a wider range of interventions. CONCLUSIONS: There is high certainty that using nicotine replacement therapy from quit day increases smoking abstinence and no further research is required. Evidence is less certain that nicotine replacement increases abstinence when used in higher doses tailored to particular groups of smokers or use prior to quit day and further research would be helpful. There is moderate certainty evidence to support the use of e-cigarettes as cessation aids, but research on their role in preventing relapse would be particularly helpful.

Original publication




Journal article



Publication Date



Behavioural interventions, Cochrane, Electronic cigarettes, Pharmacotherapy, Smoking, Systematic review, Tobacco